> top > docs > PMC:7200337 > spans > 53582-53841 > annotations

PMC:7200337 / 53582-53841 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-PD-FMA-UBERON

Id Subject Object Predicate Lexical cue fma_id
T532 22-36 Body_part denotes immunoglobulin http://purl.org/sig/ont/fma/fma62871

LitCovid-PD-MONDO

Id Subject Object Predicate Lexical cue mondo_id
T343 61-64 Disease denotes ADE http://purl.obolibrary.org/obo/MONDO_0019383
T344 86-94 Disease denotes COVID-19 http://purl.obolibrary.org/obo/MONDO_0100096
T345 238-246 Disease denotes SARS-CoV http://purl.obolibrary.org/obo/MONDO_0005091
T346 249-258 Disease denotes infection http://purl.obolibrary.org/obo/MONDO_0005550

LitCovid-PD-CLO

Id Subject Object Predicate Lexical cue
T661 66-69 http://purl.obolibrary.org/obo/CLO_0051582 denotes has

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
1736 199-201 Gene denotes to Gene:6999
1737 175-177 Gene denotes to Gene:6999
1742 95-103 Species denotes patients Tax:9606
1744 86-94 Disease denotes COVID-19 MESH:C000657245
1745 238-258 Disease denotes SARS-CoV-2 infection MESH:C000657245

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T294 0-259 Sentence denotes High-dose intravenous immunoglobulin (IVIg), which may blunt ADE, has been trialed in COVID-19 patients (Cao et al., 2020b, Shao et al., 2020), but further studies are needed to determine the extent to which IVIg is safe or beneficial in SARS-CoV-2 infection.